57
Participants
Start Date
November 27, 2018
Primary Completion Date
September 1, 2021
Study Completion Date
August 17, 2022
M3814
Participants received M3814 twice daily (BID) continuously starting from Day 1 until progressive disease (PD) or unacceptable toxicity.
M3814
Participants received M3814 concomitantly with RT once (QD) daily starting Day 1 for 5 days per week for 2 weeks in total.
Avelumab
Participants received avelumab once every 2 weeks (Q2W) starting from Day 1 until PD or unacceptable toxicity.
Radiotherapy
Participants received radiotherapy at the dose of 3 grays (Gy) per day starting Day 1 for 5 days per week for 2 weeks.
Mount Sinai - PRIME (10707), Lake Success
University of Pittsburgh Medical Center Health System, Pittsburgh
Greenville Hospital System University Medical Center (ITOR), Greenville
H. Lee Moffitt Cancer Center and Research Institute, Inc, Tampa
Vanderbilt-Ingram Cancer Center (8867), Nashville
The University of Chicago Medical Center, Chicago
University of Oklahoma Health Sciences Center - Stephenson Cancer Center, Oklahoma City
UC Health Clinical Trials Office (10702), Cincinnati
Merck KGaA, Darmstadt, Germany
INDUSTRY
EMD Serono Research & Development Institute, Inc.
INDUSTRY